Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients

Massa, Filippo; Crémoni, Marion; Gérard, A; Grabsi, Hanen; Rogier, L.J.J.; Blois, M.-C. De; Hassen, Nadia Ben; Rouleau, Matthieu; Barbosa, Susana; Martinuzzi, Emanuela; Fayada, Julien; Bernard, Ghislaine; Favre, Guillaume; Hofman, Paul; Esnault, Vincent; Czerkinsky, Cécil; Seitz-Polski, Barbara; Glaichenhaus, Nicolas; Sicard, A

doi:10.2139/ssrn.3890865

Cited by 5 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By end June 2021, the first global publication focusing on D3 was published, primarily involving transplanted patients (38). This was quickly followed by other series confirming the beneficial contribution of D3 in these immunocompromised patients (39)(40). In a randomized trial (41), either D3 or placebo was randomly administered to transplanted patients, using mRNA-1273 vaccine (Moderna) at Month 2 following D2 injection.…”

Section: Third Dose Data In Immunocompromised Patientsmentioning

confidence: 99%

“…Vaccine research is primarily aimed to identify a vaccine-induced humoral response that predicts protection from infection or disease (45). Immunization after viral infection and vaccine efficacy have previously been related to NAbs rates (46), thereby reducing clinical events (47) or, in specific conditions, helping consider revaccination (i.e., booster dose, challenge dose, or revaccination with a complete series) (48).…”

Section: Correlation Data Between Humoral Response and Clinical Outcomementioning

confidence: 99%

See 1 more Smart Citation

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Barrière

Carlès

Audigier-Valette

et al. 2022

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Taking into account higher risk of severe coronavirus disease 2019 (COVID-19) or death among patients with cancer, as well as impaired immunogenicity following anti-SARS-CoV-2 vaccines, in addition to waning immunity, booster dosing appears mandatory in this patient population. This review sought to provide reasonable evidence so as to assist oncologists in their daily practice, helping them decide when an anti-SARS-Cov2 antibodies (Abs) dosage should be scheduled following a full two-dose vaccination and if necessary, propose an early third dose (D3). Such D3 could apply to non-responder patients with anti-Spike (S) Abs titers < 40 binding antibody units (BAU)/mL. For low-responder patients with anti-S Abs titers between 40 BAU/mL and 100/260 BAU/mL (suggested area of uncertainty), an early D3 may similarly be proposed. Nevertheless, this D3 could be administered in a less urgent manner, taking into account associated co-morbidities and regional epidemic incidence rates. This latter strategy may comprise a monthly dosage of anti-S titers so as to better assess the kinetics of waning immunity. For responder patients with anti-S titers above 260 BAU/mL, we suggest to follow the recommendations outlined for the general population. Given this context, patients with anti-S titers above 1000 BAU/mL should be given the possibility to undergo anti-S titer control after 3 months, designed to assess rapid humoral waning immunity. We strongly recommend that patients with cancer be included into observational serological monitoring studies or clinical trials that are dedicated to severe immunocompromised patients without any humoral seroconversion after D3.

show abstract

Section: Third Dose Data In Immunocompromised Patientsmentioning

confidence: 99%

Section: Correlation Data Between Humoral Response and Clinical Outcomementioning

confidence: 99%

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Barrière

Carlès

Audigier-Valette

et al. 2022

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…For three cohort studies, of 1721 recipients, three recipients developed rejection. 3 , 4 Acute cell‐mediated rejection was seen at 8‐ and 11‐days post‐vaccination in the kidney 2 and liver transplant recipient, 5 respectively. No documented graft failure was reported.…”

Section: Tablementioning

confidence: 99%

“… 2 , 3 , 4 One/thirteen kidney transplant recipients developed donor‐specific anti‐HLA class II antibody 28 days after the second dose of BNT162b2 vaccine which increased after the third dose, without allograft rejection. 5 …”

Section: Tablementioning

confidence: 99%

Adverse events after SARS‐CoV‐2 vaccination in solid organ transplant recipients: A systematic review

Villavicencio

Ebisu

Raja

et al. 2022

Transplant Infectious Dis

View full text Add to dashboard Cite

To the Editor,The immunogenicity in solid organ transplant (SOT) recipients against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is suboptimal. 1 However, adverse events including rejection post-vaccination have not been reviewed, which are also of great interest for clinicians taking care of transplant recipients.We conducted a systematic review on adverse events post SARS-CoV-2 vaccination in SOT recipients and included studies on SOT and SARS-CoV-2 vaccine safety including (a) systemic or local reactions, (b) organ rejection or de novo donor-specific antibodies (DSAs)

show abstract

“…Few studies on a third-dose regimen have been published to date, all of which are in high-risk populations, such as transplant patients. 11,12 These reported adequate antibody responses, though follow-up time was short and cohort sizes small. Recently, Pfizer and BioNTech released a statement regarding a reported on-going trial, in which a booster was administered 6 months after the second dose.…”

Section: Introductionmentioning

confidence: 98%

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine

Patalon

Gazit

Pitzer

et al. 2021

Preprint

View full text Add to dashboard Cite

With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose regimen against infection due to the Delta variant of SARS-CoV-2, using two complementary approaches; a test-negative design and a matched case-control design. We found that 7-13 days after the booster shot there is a 48-68% reduction in the odds of testing positive for SARS-CoV-2 infection and that 14-20 days after the booster the marginal effectiveness increases to 70-84%. Further studies are needed to determine the duration of protection conferred by the third dose and its effect on severe disease.

show abstract

Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients

Cited by 5 publications

References 8 publications

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Adverse events after SARS‐CoV‐2 vaccination in solid organ transplant recipients: A systematic review

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine

Contact Info

Product

Resources

About